SEARCH

SEARCH BY CITATION

Dear Sir,

We greatly appreciate the interest in our recent pharmacoepidemiological study of cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs [1]. We agree with Balta and colleagues that further studies are needed to evaluate the impact on cardiovascular risk of individual systemic antipsoriatic therapies. Also, as mentioned in our report [1], we fully acknowledge the limitations of our study and the need for large-scale randomized clinical trials to determine the cardiovascular safety and efficacy of individual systemic antipsoriatic drugs. Before such data become available; however, we believe that studies such as ours add considerable weight to the evolving evidence base underlying the perceived benefit/risk ratio of systemic antipsoriatic therapies.

Conflict of interest statement

  1. Top of page
  2. Conflict of interest statement
  3. References

There is no conflict of interest to declare.

References

  1. Top of page
  2. Conflict of interest statement
  3. References